These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 19665054)
1. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. Corbin JD; Zoraghi R; Francis SH Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054 [TBL] [Abstract][Full Text] [Related]
2. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. Corbin JD; Francis SH Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965 [TBL] [Abstract][Full Text] [Related]
3. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142 [TBL] [Abstract][Full Text] [Related]
4. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. Biswas KH; Visweswariah SS J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396 [TBL] [Abstract][Full Text] [Related]
5. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306 [TBL] [Abstract][Full Text] [Related]
6. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Turko IV; Ballard SA; Francis SH; Corbin JD Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. Bessay EP; Blount MA; Zoraghi R; Beasley A; Grimes KA; Francis SH; Corbin JD J Pharmacol Exp Ther; 2008 Apr; 325(1):62-8. PubMed ID: 18199808 [TBL] [Abstract][Full Text] [Related]
10. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11. Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068 [TBL] [Abstract][Full Text] [Related]
11. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Zoraghi R; Francis SH; Corbin JD Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301 [TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Corbin JD; Turko IV; Beasley A; Francis SH Eur J Biochem; 2000 May; 267(9):2760-7. PubMed ID: 10785399 [TBL] [Abstract][Full Text] [Related]
13. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278 [TBL] [Abstract][Full Text] [Related]
14. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347 [TBL] [Abstract][Full Text] [Related]
15. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324 [TBL] [Abstract][Full Text] [Related]
16. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179 [TBL] [Abstract][Full Text] [Related]
17. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Li N; Xi Y; Tinsley HN; Gurpinar E; Gary BD; Zhu B; Li Y; Chen X; Keeton AB; Abadi AH; Moyer MP; Grizzle WE; Chang WC; Clapper ML; Piazza GA Mol Cancer Ther; 2013 Sep; 12(9):1848-59. PubMed ID: 23804703 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. Zoraghi R; Corbin JD; Francis SH J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275 [TBL] [Abstract][Full Text] [Related]
19. Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. Zhang XJ; Cahill KB; Elfenbein A; Arshavsky VY; Cote RH J Biol Chem; 2008 Oct; 283(44):29699-705. PubMed ID: 18779324 [TBL] [Abstract][Full Text] [Related]
20. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Gopal VK; Francis SH; Corbin JD Eur J Biochem; 2001 Jun; 268(11):3304-12. PubMed ID: 11389733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]